Details of the Drug

General Information of Drug (ID: DMI7JF3)

• Drug Name: Lucerastat
• Synonyms: 141206-42-0; UNII-GVS3YDM418; N-Butyldeoxygalactonojirimycin; GVS3YDM418; CHEMBL1086997; N-(n-Butyl)deoxygalactonojirimycin; (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; Lucerastat [INN]; N-Butyl-DGJ; NB-DGJ; N-Bu-DGJ; AC1L9UXN; N- Butyldeoxygalactonojirimycin; SCHEMBL6821044; N-Butyl-deoxy-galactonojirimycin; CDP-923; N-N-Butyl Deoxygalactonojirimycin; OGT-923; DTXSID60161601; MolPort-039-015-418; ZX-AT009021; ZINC13719785; BDBM50312528; N-Butyl-D-galacto-1-deoxynojirimycin; AKOS027384398; NCGC00181326

Indication

Disease Entry	ICD 11	Status	REF
Fabry disease	5C56.01	Phase 3	[1]

• Chemical Identifiers:
  Formula: C10H21NO4
  Canonical SMILES: CCCCN1CC(C(C(C1CO)O)O)O
  InChI: InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9+,10-/m1/s1
  InChIKey: UQRORFVVSGFNRO-XFWSIPNHSA-N
• Cross-matching ID:
  PubChem CID: 501391
  ChEBI ID: CHEMBL1086997
  CAS Number: 141206-42-0
  UNII: GVS3YDM418
  DrugBank ID: DB14872
  TTD ID: D0RE9C
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

References

• [1] ClinicalTrials.gov (NCT03737214) A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease. U.S. National Institutes of Health.